Type 1 regulatory T cells (Tr1s) are an inducible subtype of regulatory T cells that can play a beneficial (autoimmune diseases, allergy, hematological malignancies) or detrimental role (some solid tumors and infectious diseases) in human diseases. Tr1 cells.
Researchers at Stanford have developed a novel deep-learning-based tool called CytoTRACE2 that interprets single-cell RNA sequencing (scRNA-seq) to enable the discovery of regenerative cells across all tissue types and novel targets in cancer and other diseases.
There is broad potential to modulate RNA using small molecules, replacing more costly and difficult-to-administer oligonucleotide therapies. However, methods for screening for such small molecules are lacking.
Stem cells are generally influenced by a microenvironmental niche, typically comprised of epithelial and mesenchymal cells and extracellular substrates. Many attempts have been made to produce culture systems that mimic normal intestinal epithelial growth and differentiation.
Patients with celiac disease have a pathological reaction to gluten and have either HLA-DQ2+ (90%) or HLA-DQ8+, but expression of these MHC class II haplotypes is not sufficient and other factors are necessary for the development of celiac sprue.
Researchers at Stanford have found that a vaccine, enhanced with adjuvants that imprint an antiviral state on innate immune cells and non-hematopoietic organ cells, could confer lasting nonspecific protection against diverse pathogens.
Brief Description: Inventors at Stanford have developed a novel fiber-optic technology to achieve unprecedented sensitivity and immunity to motion artifacts that can be used in freely moving animals.
Inventors at Stanford have developed a novel strategy to perform concurrent fluorescence measurements of multiple biological parameters in freely moving and head-restrained animals.
A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
Pharmacologic agents are commonly used to treat psychiatric diseases. These compounds, however, react differently across patients, are often followed by negative side effects and can have varied efficacy timeframes.
Stanford researchers have developed technology enabling pooling and simultaneous testing of engineered T cells from multiple human donors. This invention increases scale and reduces costs for diagnostic, and pre-clinical development of engineered T cell therapies.
Stanford researchers have developed a next-generation protein sequencing platform capable of identifying all the proteins in a cell at single amino acid resolution.